Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents

NCT04490018 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT04490018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04490018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix®, and When Administered Alone or Concomitantly With 9vHPV and Tdap-IPV Vaccines in Healthy Adolescents
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 3
Overall status
Completed
Start date
March 16, 2021
Completion date
May 11, 2022
Enrollment
463 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, meningococcal immunisation